MEGGLE brings DPI insights and further InhaLac® innovation to RDD Asia

Wasserburg, Germany: – Pharmaceutical lactose experts MEGGLE Excipients & Technology (MEGGLE) will launch its latest dry powder inhalation grade product, InhaLac® 160, at the Asian Respiratory Drug Delivery, RDD 2018, in Kerala, India.

MEGGLE will also use RDD Asia to host a specialist interactive session on using purpose-formulated lactose grades in (DPI) formulations as part of the conference’s workshop track on Day Two of the event (November 15).

InhaLach® 160: pulmonary and nasal applications

The new InhaLac® 160 is characterized by a median particle size of approximately 110 μm, which ranges between the coarser lactose InhaLac® 120 and the finer lactose InhaLac® 230. This new excipient exhibits a narrowly distributed particle size with a fines content (particles below 15 μm) of only 3%.

This GMP/GDP certified sieved lactose is therefore suitable for pulmonary and nasal drug delivery and offers a range of benefits that include a dedicated production process, highly controlled powder characteristics, highest microbial quality including low endotoxins and retesting after 24 months.

“This new InhaLac product rounds out our inhalative grade lactose portfolio, closing the narrow gap that existed in our range of coarse sieved lactose grades for dry powder inhalation,” commented MEGGLE Head of Marketing, Christoph Adler.

DPI Formulations workshop

The MEGGLE workshop ‘Get the Right Grade- An Inhalative Lactose Guide for DPI Formulations’ will use case studies and a live demonstration to explain how the particle size of the carrier significantly changes the delivered dose and fine particle fraction of DPIs.

It will provide insights into the complex relationships between carrier lactose properties and delivery device characteristics to reveal what type of carrier is most suitable for which type of device. The case studies will also explore how lactose fines are often used in conjunction with carrier lactose (ternary powder formulations) to optimize DPI performance.

The one hour workshop will include a demonstration and questions, designed for up to 40 RDD delegates to explore detailed issues and encourage audience interaction and will be repeated three times during the conference.

Sharing knowledge worldwide

“By attending this session participants will gain a deeper understanding of what lactose carrier and fines can achieve in a DPI formulation,” commented Mr. Adler.

MEGGLE does much work to promote best practice and knowledge sharing in the dry inhalation community worldwide and share its world-leading technical expertise on co-processed lactose, anhydrous and lactose monohydrate-based excipients.

It recently joined leading sponsors, instigators and participants to host the ‘Inhalation Insights’ series of symposiums touring the Eastern United States. The events provided discussion and new perspectives on latest DPI technologies and processes, targeted at researchers and technicians working in the sector.

MEGGLE is proud to be part of this “Inhalation Insights” expert group.

About MEGGLE Wasserburg

Bavarian-based MEGGLE Wasserburg is one of the world’s experts in lactose-based excipients and powder technology.

From its roots as a dairy operation in the late 1880s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical lactose, supplying the pharma market segment with a broad-based and unique lactose product portfolio.

MEGGLE Excipients & Technology has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-tech, functional products for solid dosage form applications, where they can deliver maximum performance.

The company has introduced several pioneering products, notably Tablettose®, the world’s first agglomerated lactose for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first direct compression co-processed excipient using a hypromellose-lactose base for modified sustained release and controlled release formulations.

About RDD Asia 2018

The 2018 Asian Respiratory Drug Delivery Conference (RDD Asia 2018) is a three day event opening November 14 at the Grand Hyatt Kochi in Kerala, India.

The conference will cover a wide range of respiratory drug solutions and technologies, with sessions focusing on Advancing Regulatory Science of Inhaled and Nasal Products, Predictive Models to Support Inhalation Science and Satisfying Patient Needs in the Global Marketplace.

A further session will include a range of interactive workshops hosted by leading providers.

The conference will be opened by Professor Richard N. Dalby of the University of Maryland’s School of Pharmacy and the plenary lecture on ‘Challenging the Bioequivalence Hurdles for OINDPs: Achieving Q3 Structural Equivalence’ will be delivered by Dr. Robert Price, from the , Department of Pharmacy and Pharmacology at the UK’s University of Bath.

The conference will also feature a scientific poster session and co-located Technology Exhibition and will conclude with a Gala Dinner.

The event is organized by RDD Online with further information at:
https://www.rddonline.com/rdd/rdd.php?id=16&sid=1.